Literature DB >> 16597680

Relaxin improves renal function and histology in aging Munich Wistar rats.

Lee A Danielson1, Angela Welford, Alexis Harris.   

Abstract

Administration of recombinant human relaxin (rhRLX) to conscious, chronically instrumented rats increases GFR and effective renal plasma flow (ERPF) and decreases effective renal vascular resistance (ERVR) with no significant change in mean arterial pressure. The Munich Wistar albino rat shows progressive chronic nephrosis with age and therefore was used to determine the functional and histologic consequences of rhRLX on matrix remodeling in the kidney of older rats. RLX-infused rats showed increased GFR and ERPF with decreased ERVR. Furthermore, in a double-blinded examination, the renal histology showed a significant decrease in glomerular and tubular collagen deposition in the rhRLX-infused aged rats. During short-term rhRLX administration (24 h), gelatinase activity was found to be essential for renal vasodilation and hyperfiltration. Surprisingly, after 20 d, improved renal function was insensitive to the inhibition of gelatinase activity, suggesting that collagen degradation in these rats had permanently altered the matrix of the renal vasculature. In conclusion, long-term administration of rhRLX improves renal function and ameliorates renal pathology in an aging rat model. The biphasic action of rhRLX on the kidney indicates that, acutely, the vessels dilate, causing increased filtration and renal blood flow with decreased vascular resistance as a result of upregulation of gelatinase activity. Subsequently, the renal vessels undergo alteration in supporting matrix, showing increased blood supply even in the face of acute matrix metalloproteinase inhibition, most likely as a result of the inhibitory properties of RLX on collagen production or increased collagen breakdown.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16597680     DOI: 10.1681/ASN.2005121307

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  24 in total

Review 1.  Effects of relaxin on arterial dilation, remodeling, and mechanical properties.

Authors:  Kirk P Conrad; Sanjeev G Shroff
Journal:  Curr Hypertens Rep       Date:  2011-12       Impact factor: 5.369

Review 2.  The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.

Authors:  Jennifer M Sasser
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

3.  Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(ω)-nitro-L-arginine methyl ester hypertensive rats.

Authors:  Jennifer M Sasser; Miklos Molnar; Chris Baylis
Journal:  Hypertension       Date:  2011-06-13       Impact factor: 10.190

Review 4.  Maternal vasodilation in pregnancy: the emerging role of relaxin.

Authors:  Kirk P Conrad
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-05-25       Impact factor: 3.619

Review 5.  Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.

Authors:  Roland E Schmieder; Veselin Mitrovic; Christian Hengstenberg
Journal:  Clin Res Cardiol       Date:  2015-03-19       Impact factor: 5.460

Review 6.  Emerging role of relaxin in the maternal adaptations to normal pregnancy: implications for preeclampsia.

Authors:  Kirk P Conrad
Journal:  Semin Nephrol       Date:  2011-01       Impact factor: 5.299

7.  Relaxin-mediated renal vasodilation in the rat is associated with falls in glomerular blood pressure.

Authors:  Aihua Deng; Kirk Conrad; Chris Baylis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-10-18       Impact factor: 3.619

8.  AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac Fibrosis.

Authors:  Bryna S M Chow; Martina Kocan; Matthew Shen; Yan Wang; Lei Han; Jacqueline Y Chew; Chao Wang; Sanja Bosnyak; Katrina M Mirabito-Colafella; Giannie Barsha; Belinda Wigg; Elizabeth K M Johnstone; Mohammed A Hossain; Kevin D G Pfleger; Kate M Denton; Robert E Widdop; Roger J Summers; Ross A D Bathgate; Tim D Hewitson; Chrishan S Samuel
Journal:  J Am Soc Nephrol       Date:  2019-09-11       Impact factor: 10.121

Review 9.  Unveiling the vasodilatory actions and mechanisms of relaxin.

Authors:  Kirk P Conrad
Journal:  Hypertension       Date:  2010-05-24       Impact factor: 10.190

Review 10.  Relaxin: review of biology and potential role in treating heart failure.

Authors:  Sam L Teichman; Elaine Unemori; John R Teerlink; Gad Cotter; Marco Metra
Journal:  Curr Heart Fail Rep       Date:  2010-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.